{"id":"W4387810275","doi":"10.1016/j.annonc.2023.09.2761","title":"1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital Saint-Luc; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"Astellas Pharma; AstraZeneca; Chugai Pharmaceutical; Pfizer","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Androgen receptor; Oncology; Pharmacology; Pharmacokinetics; Clinical endpoint; Androgen deprivation therapy; Antiandrogens; Clinical trial; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001004604,0.001904947,0.002335688,0.000467681,0.0003919403,0.0009427674,0.0009146542,0.001115221,0.008260446],"category_scores_gemma":[0.0006900142,0.000514339,0.001412295,0.0005479,0.001079536,0.0008390045,0.0003350405,0.003872917,0.001683581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000887082,"about_ca_system_score_gemma":0.001802074,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002292367,"about_ca_topic_score_gemma":0.005690265,"domain_scores_codex":[0.9997405,0.0001226869,0.000009256854,0.00004591979,0.00002096589,0.00006052183],"domain_scores_gemma":[0.9996169,0.0000661179,0.00006474452,0.00002585503,0.00002385448,0.0002025433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8561555,0.02328248,0.001509652,0.000705871,0.001322456,0.00008608515,0.0001028108,0.001428347,0.01358678,0.0003647947,0.00745104,0.09400427],"study_design_scores_gemma":[0.7520761,0.2349207,0.005650159,0.00004349711,0.0007428208,0.0001488164,0.00004534792,0.0008295605,0.001767243,0.0003586291,0.003383808,0.00003322322],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743229,0.005917066,0.001148564,0.001959732,0.0004386999,0.002846631,0.004700078,0.0005680672,0.008098317],"genre_scores_gemma":[0.9677883,0.005653422,0.00312832,0.002343284,0.0004296265,0.002409271,0.006143698,0.0001329255,0.01197114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008260446,"threshold_uncertainty_score":0.02763397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2061185689696446,"score_gpt":0.5020156712325335,"score_spread":0.295897102262889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}